Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results

被引：0

作者：

Stein, Mark R. ^{[1
]}

Wasserman, Richard L. ^{[2
]}

Melamed, Isaac ^{[3
]}

Rubinstein, Arye ^{[4
,5
]}

Puck, Jennifer ^{[6
]}

Gupta, Sudhir ^{[7
]}

Engl, Werner ^{[8
]}

Leibl, Heinz ^{[8
]}

McCoy, Barbara ^{[8
]}

Yel, Leman ^{[9
]}

Schiff, Richard I. ^{[9
]}

机构：

[1] Allergy Associates Palm Beaches, North Palm Beach, FL USA

[2] DallasAllergyImmunol, Dallas, TX USA

[3] IMMUNOe Hlth Ctr, Centennial, CO USA

[4] Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Montefiore Med Ctr, Bronx, NY 10467 USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Calif Irvine, Irvine, CA USA

[8] Baxter BioSci, Vienna, Austria

[9] Baxter BioSci, Westlake Village, CA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：380 / 381

页数：2

共 50 条

[1] Patient Preferences for Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHy) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
Ito, Diane
Ye, Xiaolan
Xiong, Yan
Li-McLeod, Josephine
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 376 - 376
[2] Safety and Pharmacokinetics (Pk) of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Extension Study of a Phase 3 Pivotal Trial
Melamed, Isaac
Wasserman, Richard L.
Stein, Mark R.
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 379 - 379
[3] Patient Preferences for Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHY) in Adults with Primary Immunodeficiencies (PI): Phase 3 Study Results
Ito, D.
Ye, X.
Xiong, Y.
Li-McLeod, J.
Schiff, R.
Faivre, P.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S381 - S382
[4] Long Term Safety, Efficacy, and Tolerability of Recombinant Human Hyaluronidase [RHUPH20] -Facilitated Subcutaneous Infusion of Immunoglobulin G (IGG) (HYQVIA; IGHY) in Adults with Primary Immunodeficiencies (PI)
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S310 - S311
[5] Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)
Wasserman, Richard L.
Stein, Mark R.
Melamed, Isaac
Kobrynski, Lisa J.
Gupta, Sudhir
Puck, Jennifer M.
Rubinstein, Arye
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB96 - AB96
[6] RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNO GLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PI): LONG TERM SAFETY, EFFICACY, AND TOLERABILITY.
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A89 - A89
[7] LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID)
Wasserman, Richard L.
Melamed, Isaac
Stein, Mark
Kobrynski, Lisa
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 314 - 314
[8] EFFICACY, SAFETY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN ADULT PATIENTS WITH PRIMARY IMMUNODEFICIENCIES: PHASE 3 STUDY RESULTS
Stein, Mark
Wasserman, Richard L.
Melamed, Isaac
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
McCoy, Barbara
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 727 - 727
[9] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF STUDY PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
Wasserman, R. L.
Melamed, I.
Stein, M.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 155 - 156
[10] A PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE (rHuPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN (IG) (IGHY) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sommer, C.
England, J.
Jakobsen, J.
Reeve, R.
Oh, M. S.
Ngo, L. Y.
Tobias, K.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 235 - 235

← 1 2 3 4 5 →